Berenberg Bank Begins Coverage on Blueprint Medicines (NASDAQ:BPMC)
Berenberg Bank Begins Coverage on Blueprint Medicines (NASDAQ:BPMC)
Berenberg Bank assumed coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) in a research note published on Wednesday, The Fly reports. The firm issued a buy rating and a $90.00 price target on the biotechnology company's stock.
据The Fly报道,贝伦贝格银行在周三发布的一份研究报告中对Blueprint Medicines(纳斯达克代码:BPMC-GET Rating)的股票进行了报道。该公司对这家生物技术公司的股票发布了买入评级和90.00美元的目标价。
A number of other analysts also recently issued reports on BPMC. Credit Suisse Group raised their target price on Blueprint Medicines from $80.00 to $90.00 in a research note on Wednesday, September 7th. SVB Leerink cut their target price on Blueprint Medicines from $65.00 to $57.00 and set a market perform rating for the company in a research note on Thursday, August 18th. HC Wainwright cut their target price on Blueprint Medicines from $100.00 to $80.00 and set a buy rating for the company in a research note on Wednesday, August 17th. Stifel Nicolaus raised their target price on Blueprint Medicines from $93.00 to $100.00 and gave the stock a buy rating in a research note on Thursday, August 18th. Finally, Jefferies Financial Group raised their target price on Blueprint Medicines from $78.00 to $84.00 and gave the stock a buy rating in a research note on Monday, August 22nd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Blueprint Medicines presently has an average rating of Moderate Buy and a consensus price target of $92.06.
其他一些分析师最近也发布了关于BPMC的报告。瑞士信贷集团在9月7日周三的一份研究报告中将Blueprint Medicines的目标价从80.00美元上调至90.00美元。SVB Leerink在8月18日周四的一份研究报告中将Blueprint Medicines的目标价从65.00美元下调至57.00美元,并为该公司设定了市场表现评级。8月17日,HC Wainwright在一份研究报告中将Blueprint Medicines的目标价从100.00美元下调至80美元,并为该公司设定了买入评级。Stifel Nicolaus将Blueprint Medicines的目标价从93美元上调至100.00美元,并在8月18日周四的一份研究报告中给出了该股的买入评级。最后,杰富瑞金融集团将Blueprint Medicines的目标价从78.00美元上调至84.00美元,并在8月22日(星期一)的一份研究报告中给予该股买入评级。两名研究分析师对该股的评级为卖出,四名分析师给出了持有评级,八名分析师给出了买入评级,一名分析师对该公司发出了强烈的买入评级。根据MarketBeat的数据,Blueprint Medicines目前的平均评级为中等买入,共识目标价为92.06美元。
Blueprint Medicines Stock Performance
蓝图药品类股表现
Shares of BPMC stock opened at $69.23 on Wednesday. The stock's fifty day moving average is $64.87 and its two-hundred day moving average is $60.98. The firm has a market capitalization of $4.12 billion, a P/E ratio of -5.83 and a beta of 0.78. Blueprint Medicines has a fifty-two week low of $43.46 and a fifty-two week high of $117.86.
周三,BPMC股票开盘报69.23美元。该股的50日移动均线切入位为64.87美元,200日移动均线切入位为60.98美元。该公司的市值为41.2亿美元,市盈率为-5.83,贝塔系数为0.78。Blueprint Medicines的股价为52周低点43.46美元,52周高位为117.86美元。
Insider Buying and Selling at Blueprint Medicines
Blueprint Medicines的内幕买卖
In other Blueprint Medicines news, insider Debra Durso-Bumpus sold 5,000 shares of Blueprint Medicines stock in a transaction dated Wednesday, August 24th. The stock was sold at an average price of $75.11, for a total value of $375,550.00. Following the completion of the transaction, the insider now directly owns 40,836 shares of the company's stock, valued at approximately $3,067,191.96. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Jeffrey W. Albers sold 10,000 shares of Blueprint Medicines stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $70.07, for a total value of $700,700.00. Following the completion of the transaction, the director now owns 183,243 shares in the company, valued at approximately $12,839,837.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Debra Durso-Bumpus sold 5,000 shares of Blueprint Medicines stock in a transaction dated Wednesday, August 24th. The shares were sold at an average price of $75.11, for a total value of $375,550.00. Following the completion of the transaction, the insider now owns 40,836 shares of the company's stock, valued at approximately $3,067,191.96. The disclosure for this sale can be found here. Insiders sold a total of 47,500 shares of company stock valued at $3,300,123 in the last three months. 3.42% of the stock is owned by corporate insiders.
在Blueprint Medicines的其他新闻中,内部人士Debra Durso-Bumpus在8月24日星期三的交易中出售了5,000股Blueprint Medicines股票。这只股票的平均售价为75.11美元,总价值为375,550.00美元。交易完成后,这位内部人士现在直接持有该公司40,836股股票,价值约3,067,191.96美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,通过这个超级链接可以访问微博。在其他新闻方面,董事杰弗里·W·阿尔伯斯在一笔日期为8月8日(星期一)的交易中出售了10,000股Blueprint Medicines股票。这只股票的平均售价为70.07美元,总价值为700,700.00美元。交易完成后,董事现在拥有该公司183,243股,价值约12,839,837.01美元。这笔交易是在提交给美国证券交易委员会(Securities&Exchange Commission)的一份文件中披露的,可以通过这个链接访问。此外,内部人士Debra Durso-Bumpus在一笔日期为8月24日星期三的交易中出售了5000股Blueprint Medicines股票。这些股票的平均价格为75.11美元,总价值为375,550.00美元。交易完成后,这位内部人士现在拥有该公司40,836股股票,价值约3,067,191.96美元。此次拍卖的披露信息可在此处找到。在过去的三个月里,内部人士总共出售了47,500股公司股票,价值3,300,123美元。3.42%的股份由企业内部人士持有。
Hedge Funds Weigh In On Blueprint Medicines
对冲基金看好Blueprint Medicines
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Exane Derivatives boosted its stake in shares of Blueprint Medicines by 45.8% in the 1st quarter. Exane Derivatives now owns 567 shares of the biotechnology company's stock valued at $36,000 after buying an additional 178 shares during the period. Van ECK Associates Corp lifted its stake in Blueprint Medicines by 16.0% during the first quarter. Van ECK Associates Corp now owns 1,548 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 213 shares during the last quarter. Synovus Financial Corp lifted its stake in Blueprint Medicines by 1.0% during the fourth quarter. Synovus Financial Corp now owns 21,405 shares of the biotechnology company's stock worth $2,293,000 after purchasing an additional 219 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Blueprint Medicines by 50.7% during the second quarter. Nisa Investment Advisors LLC now owns 684 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 230 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in Blueprint Medicines by 5.3% during the fourth quarter. Canada Pension Plan Investment Board now owns 6,183 shares of the biotechnology company's stock worth $662,000 after purchasing an additional 312 shares during the last quarter.
几家对冲基金和其他机构投资者最近改变了他们在该股的头寸。Exane衍生品在第一季度将其在Blueprint Medicines的股份增加了45.8%。在此期间,Exane衍生品公司又购买了178股,现在拥有567股这家生物技术公司的股票,价值3.6万美元。Van Eck Associates Corp在第一季度将其在Blueprint Medicines的持股比例提高了16.0%。Van Eck Associates Corp在上个季度额外购买了213股后,现在拥有这家生物技术公司1,548股股票,价值99,000美元。Synovus Financial Corp在第四季度增持了Blueprint Medicines 1.0%的股份。Synovus Financial Corp现在持有这家生物技术公司21,405股股票,价值2,293,000美元,此前该公司在上个季度又购买了219股。NISA Investment Advisors LLC在第二季度增持了50.7%的Blueprint Medicines股份。NISA Investment Advisors LLC现在持有这家生物技术公司684股股票,价值3.5万美元,在上个季度又购买了230股。最后,加拿大养老金计划投资委员会在第四季度将其在Blueprint Medicines的持股比例提高了5.3%。加拿大养老金计划投资委员会在上个季度额外购买了312股后,现在拥有这家生物技术公司6183股票,价值66.2万美元。
Blueprint Medicines Company Profile
蓝图医药公司简介
(Get Rating)
(获取评级)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.
BluePrint Medicines Corporation是一家精准治疗公司,在美国和国际上开发针对基因定义的癌症和血液疾病的药物。该公司正在开发用于治疗全身性肥大细胞增多症(SM)和胃肠道间质瘤的AYVAKIT;用于治疗非进展性肥大细胞增多症和其他肥大细胞疾病的口服可用、有效的试剂盒抑制剂BLU-263;以及用于治疗肝细胞癌的口服可用且有效的抑制剂Fisogatinib。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Blueprint Medicines (BPMC)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- 免费获取StockNews.com关于蓝图药物的研究报告(BPMC)
- 股市:红海中的三座强国
- 第四季度值得考虑的3家银行
- 有什么办法可以治愈Teladoc股票的问题吗?
- 没有人告诉这三只股票这是下跌的一周
- MarketBeat:回顾一周9/12-9/16
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
接受蓝图药物日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Blueprint Medicines和相关公司的最新新闻和分析师评级的每日摘要。